Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
(RS)-MCPG disodium salt is a sodium salt of (RS)-MCPG, a non-selective group I/group II metabotropic glutamate receptor antagonist.
S-enantiomer also available.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 253.16. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.95 mL||19.75 mL||39.5 mL|
|5 mM||0.79 mL||3.95 mL||7.9 mL|
|10 mM||0.4 mL||1.98 mL||3.95 mL|
|50 mM||0.08 mL||0.4 mL||0.79 mL|
References are publications that support the biological activity of the product.
Collingridge and Watkins (1994) Phenylglycine derivatives as metabotropic glutamate receptor antagonists. TiPS 15 333 PMID: 7992387
Joly et al (1995) Molecular, functional and pharmacological characterization of the metabotropic glutamate receptor Type 5 splice variants: comparison with mGluR1. J.Neurosci. 15 3970 PMID: 7751958
Eaton et al (1993) Competitive antagonist at metabotropic glutamate receptors by (S)-4-carboxyphenylglycine (CPG) and (RS)-α-methyl-4-carboxyphenylglycine (MCPG). Eur.J.Pharmacol.Mol.Pharmacol.Sect. 244 195
If you know of a relevant reference for (RS)-MCPG disodium salt, please let us know.
Keywords: (RS)-MCPG disodium salt, (RS)-MCPG disodium salt supplier, Non-Selective, mGlur, antagonists, Group, I, II, Receptors, mGlu2, mGlu3, mGluR2, mGluR3, Glutamate, Metabotropic, mGlu1, mGlu5, mGluR1, mGluR5, 1303994-09-3, Non-selective, mGlu, 3696, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for (RS)-MCPG disodium salt. Do you know of a great paper that uses (RS)-MCPG disodium salt from Tocris? Please let us know.
Average Rating: 5 (Based on 1 Review.)
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
(RS)-MCPG disodium salt was in use to prevent contamination of NMDA-receptor – generated response to prolonged application of glutamate with (possible) impact from metabotropic glutamate receptors (mGluRs). APV, applied after glutamate, fully suppressed NMDA-receptor response, thus suggesting no input from mGluRs (see illustration). MCPG disodium salt works as expected; the effects and time interval for response development are same with those of (RS)-MCPG, but the salt is much easier soluble.
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.